𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phosphatidylinositol Containing Lipidic Particles Reduces Immunogenicity and Catabolism of Factor VIII in Hemophilia A Mice

✍ Scribed by Aaron Peng; Robert M. Straubinger; Sathy V. Balu-Iyer

Book ID
111767660
Publisher
American Association of Pharmaceutical Scientists
Year
2010
Tongue
English
Weight
246 KB
Volume
12
Category
Article
ISSN
1550-7416

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phosphatidylserine containing liposomes
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A
✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Influence of aggregation on immunogenici
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice
✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg